






































Antitumor Necrosis Factor Agents to Treat Endoscopic
Postoperative Recurrence of Crohn’s Disease: A
NationwideStudyWithPropensity-MatchedScoreAnalysis
Fiorella Cañete1,2,3, Míriam Mañosa1,2, Isabel Pérez-Martínez4, Manuel Barreiro-de Acosta5, Ramiro C. González-Sueyro6, Pilar Nos2,7,
Eva Iglesias-Flores8, Ana Gutiérrez9, Luis Bujanda2,10, Jordi Gordillo11, Raquel Ríos León12, María José Casanova2,13, Albert Villoria2,3,14,
Iago Rodríguez-Lago15,16, Pilar López Serrano17, Antonio García-Herola18, Patricia Ramírez-de la Piscina19, Mercè Navarro-Llavat20,
Carlos Taxonera21,22, Jesús Barrio23, Laura Ramos24, Pablo Navarro25, Olga Benítez-Leiva26, Margalida Calafat1,3 and
Eugeni Domènech, MD, PhD1,2, on behalf of the INFLIRECU study
INTRODUCTION: Patients with Crohn’s disease experiencing endoscopic postoperative recurrence (POR) may benefit
from antitumor necrosis factor (TNF) agents but scarce data on this are available. Our aim was to assess
the efficacy of anti-TNF in improving mucosal lesions in patients with endoscopic POR.
METHODS: Multicenter, retrospective, study of patients with Crohn’s disease who underwent therapy with anti-TNF
agents for endoscopic POR (Rutgeerts score> i1). Treatment outcomeswere assessed by the findings in the
last ileocolonoscopyperformedafter anti-TNF therapywas initiated.Endoscopic improvementand remission
were defined as any reduction in the baseline Rutgeerts score and by a Rutgeerts score < i2, respectively.
RESULTS: A total of 179 patients were included, 83 were treated with infliximab and 96 with adalimumab. Median
time on anti-TNF therapy at the last endoscopic assessment was31months (interquartile range, 13–54).
Endoscopic improvement was observed in 61%, including 42% who achieved endoscopic remission.
Concomitant use of thiopurines and treatment with infliximab were associated with endoscopic
improvement (odds ratio [OR] 2.15, 95% confidence interval [CI] 1.04–4.46; P5 0.03, and OR 2.34,
95% CI 1.18–4.62; P < 0.01, respectively) and endoscopic remission (OR 3.16, 95% CI 1.65–6.05;
P < 0.01, and OR 2.01, 95% CI 1.05–3.88; P5 0.04, respectively) in the multivariable logistic
regression analysis. These results were confirmed in a propensity-matched score analysis.
DISCUSSION: In patients with endoscopic POR, anti-TNF agents improve mucosal lesions in almost two-thirds of the
patients. In this setting, concomitant use of thiopurines and use of infliximab seem to bemore effective
in improving mucosal lesions.
SUPPLEMENTARY MATERIAL accompanies this paper at http://links.lww.com/CTG/A339, http://links.lww.com/CTG/A340, and http://links.lww.com/CTG/A341
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Crohn’s disease (CD) is a chronic condition of unknown origin
which leads, in most patients, to cumulative transmural in-
testinal tissue damage that causes disease-related complica-
tions, including intestinal strictures and intra-abdominal
penetrating complications. These complications often require
a surgical approach, and, despite the current availability of
new, potent anti-inflammatory biological drugs, a noteworthy
proportion of patients with CD must still undergo intestinal
resection (1,2). Unfortunately, surgery is not curative and 70%
of patients go on to develop new intestinal lesions in the
neoterminal ileum within the first year if no therapy is pre-
scribed early after surgery (3), a process known as post-
operative recurrence (POR).
Active smoking, penetrating disease behavior, perianal disease,
andprevious intestinal resectionhave been identified as risk factors
for POR (4,5). Nonetheless, these factors do not afford an adequate
prediction of POR nor a stratification of patients for prevention
strategies, and patients may be overtreated or undertreated if a
systematic policy is followed in this scenario. Therefore, the ap-
propriateness of preventive therapies is still amatter of debate, even
in patients at a high risk of POR (6). The fact that mucosal lesions
(as assessed by ileocolonoscopy and called endoscopic POR) occur
early after surgery and always precede the development of symp-
toms (clinical POR) (4), and the existence of a fine correlation
between their severity and the likeliness of developing clinical POR
(3), are the main arguments for advising early endoscopic moni-
toring in these patients, regardless of the fact that preventive
therapy has been initiated (7–9). In the absence of lesions or in
cases of mild mucosal lesions, some guidelines recommend a
conservative attitude, together with a close monitoring with non-
invasive diagnostic tools afterward (8,10). By contrast, if severe
lesions are noticed in this endoscopic assessment, treatment esca-
lation is strongly recommended (8,9).
Among the many drugs that have been tested in this clinical
setting, only thiopurines and antitumor necrosis factor (TNF)
agents have proven to be efficient in preventing endoscopic and
clinical POR (11,12). The POCER study, a randomized clinical
trial (RCT) designed to compare early vs conventional endo-
scopic monitoring, demonstrated that early treatment escalation
in patients with severe lesions results in a better short-term out-
come even if they were on preventive therapy with thiopurines
or adalimumab (13). It therefore seems reasonable that anti-TNF
agents should be used in patients developing endoscopic
POR while on thiopurines or even in those patients who did
not undergo any preventive therapy. Nevertheless, in the setting
of asymptomatic patients with endoscopic POR, only one
RCT comparing the usefulness of azathioprine and oral
aminosalicylates 5-ASA in the prevention of clinical POR has
been published to date, and no other drugs have been evaluated by
the means of RCTs for the treatment of confirmed endoscopic
POR (14). For anti-TNF agents, only some retrospective series
and small, open studies are available, reflecting the need for
further data on this issue (15–17), and the number of patients
starting adalimumab therapy for endoscopic POR in the POCER
study was rather small (13).
The aim of this study was to describe the use of infliximab and
adalimumab for the treatment of endoscopic POR in clinical
practice, to assess and compare their effectiveness, and to identify
the factors associated with treatment outcomes.
METHODS
Study population
This is a retrospective, multicenter, observational study including
all those patients with CD who underwent an intestinal resection
with ileocolonic anastomosis and who were treated with anti-TNF
agents (infliximab or adalimumab) after a diagnosis of endoscopic
POR (defined by a Rutgeerts endoscopic score. i1) (3), regardless
of concurrent clinical symptoms. Patients were identified from the
local IBD databases of each participating center. CD diagnosis was
based on the accepted criteria of the European Crohn’s and Colitis
Organization (18). To be included in the study, patients had tohave
undergone an endoscopic examination at least 6 months after
starting anti-TNF therapy for POR. Exclusion criteria were the
presence of transient or definitive ostomy at the time anti-TNF
therapy was started, a Rutgeerts endoscopic score , i2 at the last
endoscopic examination before anti-TNF treatment, anti-TNF
therapy indicated for primary prevention of POR, and less than 6
months of treatment with anti-TNF therapy at the time of the last
endoscopic assessment. The collected variables and the case record
database (19) are detailed in the Supplemental Digital Content 1
(http://links.lww.com/CTG/A339).
The study was approved by the Ethics Committee of the co-
ordinating center (Hospital Universitari Germans Trias i Pujol,
Badalona, Catalonia, Spain).
Outcomes and definitions
Endoscopic response to treatment was assessed in those ileoco-
lonoscopies performed during anti-TNF therapy or within the
first 3 months after anti-TNF discontinuation. Endoscopic re-
missionwas defined as a Rutgeerts score, i2, whereas endoscopic
improvement was defined by any reduction in the baseline Rut-
geerts score. Finally, we defined advanced endoscopic POR as a
Rutgeerts endoscopic score of i3 or i4.
We also assessed the induction of clinical remission in patients
with clinical POR at the beginning of anti-TNF therapy and the
development of clinical POR during anti-TNF therapy or within
the 3 months after treatment discontinuation. For this purpose,
and given that no clinical score has been validated to date for
clinical POR and these patientsmay develop chronic diarrhea as a
consequence of ileocolic resections (i.e., intestinal bacterial
overgrowth and bile salt malabsorption), we defined clinical POR
as the presence of 2 of the following 3 criteria: weight loss, increase
in stool frequency of at least 2 bowel movements/day, and new
onset of abdominal pain.
Statistical analysis
Categorical variables were expressed as frequencies and percent-
ages. Continuous variables were described as means 6 SD or as
medians and interquartile range for cases with a skewed distribu-
tion. Normal distribution was assessed using normal Q-Q plots.
Statistical differences between groups were assessed using the x2
test for categorical variables, the Student t test, or the Fisher exact
test for continuous variables with normal distribution or the
Kruskal-Wallis test for variables with a non-normal distribution.
Univariable and multivariable logistic regression models were
performed applying the backward stepwise procedure to determine
which variables were independent predictors of endoscopic im-
provement and remission. Variables included in the multivariable
analysis were those significantly associated with the end point or



















with aP value, 0.05 in the univariable analysis. Odds ratios (ORs)
with 95% confidence intervals (CIs) are reported.
In a secondary analysis and considering the difficulty of
quantifying the association of infliximab or adalimumab with
endoscopic improvement and remission in an unbiased manner,
a propensity score analysis was also performed with a logistic
regression model. The dependent variable was receipt treatment
with infliximab, and a total of 17 covariates were selected (see
Table, Supplemental Digital Content 2, http://links.lww.com/
CTG/A340). According to the propensity score, patients were
selected by 1:1 matching without replacement using the nearest
neighbor method. A caliper width of 0.2 standardized differences
was used formatching. The balance of the baseline characteristics’
distribution between the 2 groups was evaluated using the abso-
lute standardized differences. Differences were considered sta-
tistically significant at P, 0.05. All analyses were performedwith
STATA V.13.0 (College Station, TX).
RESULTS
Baseline characteristics
A total of 179 patients were included, 96 (54%) of whom were
undergoing treatment with adalimumab and 83 (46%) with
infliximab because of endoscopic POR as conventionally defined
by a Rutgeerts endoscopic score . i1. Table 1 summarizes the
baseline characteristics of the included patients, and Supple-
mental Digital Content 2 (see Table, http://links.lww.com/CTG/
A340) details the baseline characteristics of patients in the pro-
pensity score-matched cohorts. Of note, almost two-thirds had
been exposed to thiopurines and one-third to anti-TNFs before
the index surgery. As expected, 76% of patients had at least one
well-established risk factor for POR (active smoking, penetrating
disease behavior, previous intestinal resections, or history of
perianal disease) andmore than one-third hadmore than one risk
factor, active smoking at surgery being the most common one.
Regarding CD treatment, 28% of the patients did not follow any
preventive therapy for POR after the index surgery, 16% followed
long-termmesalazine or a short course ofmetronidazole, whereas
56% were on thiopurines (alone or together with a 3-month
course of metronidazole). All these demographic and clinical
characteristics were evenly distributed between the 2 treatment
groups.
The first endoscopic assessment after the index surgery was
performed after amedian of 16months (IQR, 8–56); however, the
index ileocolonoscopy demonstrating endoscopic POR before
starting anti-TNF therapy was performed after a median of 41
months (IQR, 13–78) from surgery. Of note, 63% of the cohort
had advanced endoscopic POR at the baseline endoscopy (Rut-
geerts score . i2). Furthermore, 39 patients (22%) met the ar-
bitrarily predefined criteria for clinical POR at the beginning of
the anti-TNF therapy. Despite the presence of mucosal in-
flammatory lesions, not all patients exhibited biological evidence
of disease activity; C-reactive protein measurements were avail-
able in all the patients at the time anti-TNF therapy was started,
and only 31% of them showed levels .5 mg/L (Table 2).
Main features of anti-TNF therapy
Tables 2 and 3 summarize the main clinical and therapeutic
characteristics at the beginning of anti-TNF therapy and during
follow-up, respectively. The median interval from surgery to the
beginning of anti-TNF therapy was 44 months, with more than
77% of patients starting beyond the first year after surgery. The
median time from the index ileocolonoscopy to the beginning of
anti-TNF therapy was 2 months (IQR, 1–5), without differences
between infliximab and adalimumab-treated patients (2 [IQR,
1–6] vs 2 [IQR, 1–5] months, respectively; P 5 0.08). As men-
tioned previously, 53 patients had been exposed to anti-TNF
before the index surgery; of them, 24 (45%) were further treated
with the same anti-TNF for endoscopic POR, particularly among
those previously exposed to infliximab (67% vs 31%; P 5 0.01).
Almost all the patients followed a conventional induction and
maintenance regimen schedule for each anti-TNF drug (5 mg/kg
at weeks 0, 2, 6 and every 8 weeks for infliximab and 160 mg
followed by 80 mg and 40 mg every 2 weeks, for adalimumab).
The use of concomitant immunosuppressants was common
among both infliximab and adalimumab-treated patients.
The median time of follow-up while on anti-TNF therapy was
51 months. One-third of patients were dose escalated, almost in
half of them because of a lack of endoscopic improvement or
biological activity and a large proportion for the development of
symptoms attributed to disease activity. Moreover, one-third
discontinued the initial anti-TNF treatment, mainly because of
clinical, biological, or endoscopic worsening or the development
of drug-related adverse events. Once again, none of these features
differed between infliximab and adalimumab-treated patients.
Treatment outcomes
During the follow-up, all the patients underwent at least one en-
doscopic assessment (55% one, 31% two, and 14% three or more
colonoscopies). The first endoscopic assessment was performed
after a median of 16 months (interquartile range [IQR], 11–31)
from the initiation of anti-TNF therapy (no differences between
treatment groups), whereas the last endoscopic assessment was
performed after a median of 31 months (IQR, 13–54). At the last
endoscopic assessment performedwhile on anti-TNF therapy, 109
of 179 patients (61%) had achieved endoscopic improvement, in-
cluding 65 patients (42%) who achieved endoscopic remission.
Infliximab-treated patients showed significantly higher rates of
endoscopic response (70% vs 53%; P 5 0.02) and endoscopic re-
mission (57% vs 29%; P, 0.01) (Figure 1).
Among the 39 patients who also had clinical POR at the be-
ginning of anti-TNF therapy, 23 (59%) achieved clinical re-
mission at the end of the follow-up (61%with infliximab and 57%
with adalimumab; P5 0.80). On the other hand, among the 140
patients who were asymptomatic despite having mucosal lesions
at the beginning of anti-TNF therapy, 15 (11%) met the criteria
for clinical POR (12% with infliximab and 9% with adalimumab)
after a median time of 31 months (IQR, 7–44). The cumulative
probability of remaining free of clinical POR was 96%, 91%, and
86% at 1, 3, and 5 years, respectively. No differences were ob-
served between infliximab and adalimumab-treated patients.
Factors associated with treatment outcomes
The results of the univariable andmultivariable factors associated
with endoscopic improvement and endoscopic remission are
shown inTable 4. Infliximab therapy (as opposed to adalimumab)
for endoscopic POR (OR 3.16 [95% CI 1.65–6.05]; P , 0.01),
concomitant thiopurines (OR 2.15 [95%CI 1.04–4.46]; P5 0.03),
and the presence of clinical POR at the start of anti-TNF therapy
(OR 3.31 [95% CI 1.51–7.28]; P 5 0.03) were the factors in-
dependently associated with endoscopic remission in the multi-
variable analysis. Moreover, endoscopic improvement was
independently associated with having advanced endoscopic POR
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Table 1. Baseline characteristics of patients including clinical features at index surgery
Overall (n5 179) Infliximab (n5 83) Adalimumab (n5 96) P Value
Male gender 98 (55) 51 (61) 47 (49) 0.09
Familial with inflammatory
bowel disease
18 (10) 8 (10) 10 (11) 0.85
Active smoking at CD diagnosis 103 (58) 53 (64) 50 (52) 0.11
Disease location
Ileal 97 (54) 47 (57) 50 (52) 0.54
Ileocolonic 82 (46) 36 (43) 46 (48) 0.54
Upper gastrointestinal involvement 5 (3) 2 (2) 3 (3) 0.77
Disease behavior
Inflammatory 14 (8) 6 (7) 8 (8) 0.78
Stricturing 78 (44) 38 (46) 40 (42) 0.58
Penetrating 87 (49) 39 (47) 48 (50) 0.69
Extraintestinal manifestations 50 (28) 19 (23) 31 (32) 0.16
Rheumatologic 40 (22) 15 (18) 25 (26) 0.20
Cutaneous 13 (7) 5 (6) 8 (8) 0.55
Ocular 5 (3) 4 (5) 1 (1) 0.13
Thrombotic 1 (1) 1 (1) 0 (0) 0.28
Age group at diagnosis
,18 yr 19 (11) 7 (8) 12 (13) 0.38
18–40 yr 130 (73) 60 (72) 70 (73) 0.92
.40 yr 30 (17) 16 (19) 14 (15) 0.40
Indication of index surgery
Intestinal stenosis 92 (51) 48 (58) 44 (46) 0.11
Intra-abdominal penetrating complication 67 (37) 25 (30) 42 (44) 0.06
Refractoriness to medical therapy 20 (11) 10 (12) 10 (10) 0.73
Thiopurines exposure before
index surgery
100 (56) 50 (60) 50 (52) 0.27
Anti-TNF exposure before index surgery 53 (30) 21 (25) 32 (33) 0.24
Active smoking at index surgery 86 (48) 44 (53) 42 (44) 0.22
Heavy smokers (.10 cigarettes/d) 54 (75) 27 (77) 27 (73) 0.68
Penetrating behavior 87 (49) 39 (47) 48 (50) 0.69
Perianal disease before index surgery 30 (17) 16 (19) 14 (15) 0.40
Intestinal resections before
index surgery
30 (17) 14 (17) 16 (17) 0.97
Median (range) 1 (1–3) 1 (1–2) 1 (1–3)
At least 1 risk factor for POR 136 (76) 63 (76) 73 (76) 0.75
.1 known risk factor for POR 66 (37) 31 (37) 35 (36) 0.90
Primary prevention for POR
after index surgery
None 51 (28) 20 (24) 31 (32) 0.23
Mesalazine 11 (6) 2 (2) 9 (9) 0.06
Metronidazole 17 (10) 10 (6) 7 (4) 0.58
Thiopurines 81 (45) 40 (48) 41 (43) 0.46
Thiopurines 1metronidazole 19 (11) 11 (13) 8 (8) 0.29
CD, Crohn’s disease; POR, postoperative recurrence; TNF, tumor necrosis factor.



















(OR 2.63 [95% CI 1.37–5.07]; P , 0.01), concomitant use of
thiopurines (OR 2.34 [95% CI 1.18–4.62]; P 5 0.01), and inflix-
imab therapy for endoscopic POR (OR2.01 [95%CI 1.05–3.88];P
5 0.04). In a secondary analysis, and to establish the association
of infliximab with the outcome in an unbiased manner, a pro-
pensity score analysis was performed. Propensity score yielded 65
matched pairs of patients from both groups (infliximab and
adalimumab). The distribution of created propensity score is
presented in Supplemental Digital Content 3 (see Figure, http://
links.lww.com/CTG/A341). Infliximab therapy for POR was
significantly associated with endoscopic improvement and re-
mission (OR 2.2 [95% CI 1.1–4.5]; P5 0.03, and OR 2.2 [95% CI
1.1–4.6]; P 5 0.03, respectively).
DISCUSSION
Current guidelines on the postoperative management of CD
recommend the primary prevention of POR in all patients except
those with pure fibrotic and short ileal stenosis (8,9). However,
the need for systematic primary prophylaxis for POR is under
debate, with some authors posing the use of an endoscopic-driven
strategy in which only those patients showing mucosal lesions
would be treated (6). With this strategy, up to 55% of patients
without primary prevention will need rescue therapy within the
first year after surgery. On the other hand, even in patients who
start thiopurines early after surgery, endoscopic PORoccurs in up
to 40% within 1 year (11,20,21). Beyond the early postoperative
management of CD, it is a fact that approximately half of these
patients develop early mucosal lesions that put them at risk of
clinical POR.Mesalazine has demonstrated a very limited efficacy
in this setting (14–16,22). Thiopurines, although useful (14), are
hampered by a high rate of intolerance and their slow active
mechanism, and they may not be the most suitable option in
patients with already existing clinical POR. Therefore, biological
agents seem to be the best potential choice in this clinical scenario.
In previous small series, the reported rate of endoscopic remission
with infliximab ranged from 47% to 52% (15,17). To the best of
our knowledge, this is the largest cohort assessing the usefulness
of anti-TNF agents as rescue therapy for endoscopic POR in CD,
and we observed that anti-TNFs are able to improve or revert
recurrent mucosal lesions in more than half of the patients.
As expected, most of our patients were at a high risk of POR.
Although smoking is probably the greatest and most repeatedly
found risk factor for POR, a great proportion of patients keep on
smoking after surgery, reflecting that beyond the prescription of
efficient drug therapies, there is still room for improvement in
preventive measures by physicians and nurses in this particularly
risky clinical scenario. We also observed that half of the patients
in our cohort were treated with anti-TNF agents for endoscopic
POR despite preventive therapy with thiopurines. This might
explain that in a high proportion of our patients, anti-TNF agents
were initiated beyond the first year after the index surgery; in fact,
it has been recently reported that there is a steady risk of endo-
scopic POR over time among those patients on preventive thio-
purines with a first ileocolonoscopy withoutmucosal lesions (23).
In fact, almost half of those patients who started anti-TNF beyond
18 months after surgery had an initial ileocolonoscopy with a
Rutgeerts score, i3. Anyway, preventive thiopurine therapy for
POR, and exposure to thiopurines or anti-TNF agents before the
Table 2. Main features at the beginning of anti-TNF therapy for endoscopic POR
Overall (n5 179) Infliximab (n 5 83) Adalimumab (n5 96) P Value
Time from index surgery to index
ileocolonoscopy (mo)
41 (13–78) 40 (18–77) 46 (12–81) 0.85
Rutgeerts score at the beginning of anti-TNF
Rutgeerts i2 65 (36) 30 (36) 35 (36) 0.96
Rutgeerts i3 47 (26) 23 (28) 24 (25) 0.68
Rutgeerts i4 67 (37) 30 (36) 37 (39) 0.74
Median time (IQR) from surgery
to anti-TNF (mo)
44 (18–87) 41 (20–84) 47 (15–96) 0.82
Clinical POR at anti-TNF start 39 (22) 18 (22) 21 (22) 0.98
Exposure to the same anti-TNF prior
to index surgery
24 (45) 14 (67) 10 (31) 0.01
Anti-TNF induction schedule 176 (98) 82 (99) 94 (98) 0.65
Concomitant immunosuppressants
Thiopurines 124 (69) 62 (75) 62 (65) 0.14
Methotrexate 11 (6) 6 (7) 5 (5) 0.57
C-reactive protein .5 mg/L 55 (31) 24 (29) 31 (33) 0.63
Hemoglobin , 12 g/dL (men)
or ,11 g/dL (women)
23 (13) 11 (13) 12 (13) 0.88
Faecal calprotectin .100 mg/kga 36 (65) 17 (71) 19 (61) 0.46
Bold indicates statistical significance with a P value less than 0.05.
IQR, interquartile range; POR, postoperative recurrence; TNF, tumor necrosis factor.
aOnly available for 55 patients.
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index surgery, were not associated with a lower efficacy of anti-
TNF therapy once POR occurred. Another reason for the delay in
starting anti-TNF agents could have been the fact that treatment
escalation for POR in Spain is advised only for advanced endo-
scopic POR (8); for that matter, almost two-thirds of our patients
had advanced endoscopic POR at the index ileocolonoscopy,
Table 3. Follow-up features and outcomes of anti-TNF therapy for endoscopic postoperative recurrence
Overall (n5 179) Infliximab (n5 83) Adalimumab (n5 96) P Value
Median (IQR) follow-up time onanti-TNF (mo) 51 (30–79) 58 (30–83) 47 (27–64) 0.08
Median (IQR) time between anti-TNF start
and first endoscopic assessment (mo)
16 (11–31) 17 (11–29) 14 (10–32) 0.32
Time between anti-TNF start and first
endoscopic assessment, 18 mo
99 (55) 45 (54) 54 (56) 0.79
Median (IQR) time between anti-TNF start
and last endoscopic assessment (mo)
31 (13–54) 32 (16–58) 31 (12–47) 0.24
Anti-TNF dosemescalation 66 (37) 27 (33) 39 (41) 0.26
Reasons for anti-TNF dose escalation (could
be more than one)
Lack of endoscopic improvement 30 (45) 7 (26) 23 (59) 0.01
Digestive symptoms 42 (64) 19 (70) 23 (59) 0.34
Raised inflammatory biomarkers 10 (15) 3 (11) 7 (18) 0.35
Anti-TNF discontinuation 53 (30) 25 (30) 28 (29) 0.89
Main reasons for anti-TNF discontinuation
Clinical, biological or endoscopic
worsening
23 (49) 11 (48) 12 (50) 0.88
Adverse events 14 (30) 7 (30) 7 (29) 0.92
Other 10 (21) 5 (22) 5 (20) 0.94
Any C-reactive protein .5 mg/La 21 (12) 11 (13) 10 (11) 0.57
Any fecal calprotectin .100 mg/kgb 29 (30) 13 (33) 16 (29) 0.68
Bold indicates statistical significance with a P value less than 0.05.
IQR, interquartile range; TNF, tumor necrosis factor.
aAvailable for 176 patients.
bAvailable for 96 patients.
Figure 1. Proportion of treatment success per type of antitumor necrosis factor.



















whereas most of early endoscopic POR correspond to i2 in
reported series (13,20).
One of the most interesting findings of this study are those
factors associated with a higher efficacy of anti-TNF for im-
proving or reverting postoperative mucosal lesions. We found
that concomitant use of thiopurines increased the efficacy of
anti-TNF agents. Two RCTs comparing, respectively, infliximab
and adalimumab in monotherapy or in combination with aza-
thioprine for the treatment of active luminal CD showed that
combination therapy increased the rate ofmucosal healing after 6
months (24,25). Moreover, combination therapy is associated
with higher trough levels of anti-TNF, preventing underexposure
to the drug and potentially increasing their efficacy, particularly
whenmucosal healing is the therapeutic end point (26). Hence, it
seems reasonable that in patients with endoscopic POR in whom
anti-TNF will be started, this should be in combination with
thiopurines whenever possible, and regardless, the patients was
on preventive thiopurine therapy.
Wealso found a greater efficacy of infliximab over adalimumab.
Despite the lack of face-to-face studies, both drugs have shown
similar results in inducingmucosal healing in the settingofRCTs in
luminal CD (27). In our study, there was a significant higher
proportion of patients who had been previously exposed to the
same anti-TNF in the infliximab group; this would have been an
advantage (if any) for the adalimumab-treated patients whomight
benefit the most from a “switch strategy,” although we lack the
information on immunogenicity data. To confirm the results of the
logistic regression analysis, we performed a propensity score
analysis using 16 covariates for matching and treatment with
infliximab as the dependent variable, including 130 matched pa-
tients (65 treated with infliximab and 65 with adalimumab), and
the results remained the same. Therefore, it seems that at least in
the postoperative setting, infliximab is superior to adalimumab for
improving recurrent lesions.
Finally, we are aware of some additional limitations of our study.
First, the lack of therapeutic drug measurements. This might affect
in several ways: treatment dosing was not changed because of
therapeutic drug monitoring in most patients, and we do not know
whether those patientswhodiscontinued therapybefore surgerydid
it because of primary or secondary loss of response, with or without
dosing adjustments based on therapeutic drugmonitoring findings.
Moreover, we did not have data on immunogenicity that might be
particularly relevant in the case of reinitiation of infliximab, which
might have favored adalimumab. However, recent studies showed
controversial results regarding the utility of trough drug levels to
predict the efficacy of anti-TNF in preventing endoscopic POR
(28–30). Second, endoscopic images were not recorded, and no
central reading was possible; therefore, the information regarding
Table 4. Factors associated with treatment outcomes
Endoscopic remission Endoscopic improvement
Univariable analysis Multivariable analysis Univariable analysis Multivariable analysis
OR (95% CI) P Value OR (95% CI) P Value OR (95% CI) P Value OR (95% CI) P Value
Age at surgery 1.02 (0.99–1.05) 0.05 1.02 (0.99–1.04) 0.16
Female gender 0.90 (0.29–1.64) 0.75 0.70 (0.38–1.29) 0.26
Penetrating behavior 0.89 (0.44–1.45) 0.46 0.69 (0.38–1.26) 0.22
Perianal disease before surgery 1.26 (0.57–2.78) 0.56 1.35 (0.59–3.08) 0.48
Extraintestinal manifestations 2.36 (0.74–7.53) 0.14 1.53 (0.77–3.05) 0.23
Active smokers at index surgery 0.91 (0.50–1.65) 0.75 1.33 (0.97–1.83) 0.08
Previous intestinal resections 0.91 (0.41–2.02) 0.82 0.96 (0.43–2.13) 0.91
Anti-TNF exposure before a surgery 1.22 (0.64–2.33) 0.55 1.96 (0.98–3.93) 0.06
Advanced endoscopic POR 0.68 (0.37–1.28) 0.24 2.38 (1.27–4.45) ,0.01 2.63 (1.37–5.07) ,0.01
Postoperative prevention with
thiopurines
1.95 (1.06–3.6) 0.03 1.63 (0.89–2.98) 0.12
Concomitant thiopurines 2.21 (1.12–4.37) 0.02 2.15 (1.04–4.46) 0.03 2.26 (1.18–4.32) 0.01 2.34 (1.18–4.62) 0.01
At least 1 risk factor for POR 0.75 (0.39–1.46) 0.40 0.60 (0.29–1.25) 0.17
Clinical POR at anti-TNF start 2.79 (1.34–5.80) ,0.01 3.31 (1.51–7.28) 0.03 2.18 (0.98–4.81) 0.06
Infliximab therapy for POR 3.17 (1.71–5.88) ,0.01 3.16 (1.65–6.05) ,0.01 2.05 (1.10–3.79) 0.02 2.01 (1.05–3.88) 0.04
Time from index surgery to
anti-TNF starta
0.99 (0.99–1.00) 0.96 1.00 (0.99–1.01) 0.99
Time from CD diagnosis to
index surgerya
1.00 (0.99–1.00) 0.65 1.00 (0.99–1.00) 0.72
Endoscopic POR.12 mo
from surgery
0.85 (0.42–1.73) 0.65 0.92 (0.44–1.89) 0.81
Bold indicates statistical significance with a P value less than 0.05.
CD, Crohn’s disease; CI, confidence interval; OR, odds ratio; POR, postoperative recurrence; TNF, tumor necrosis factor.
aTime expressed in months.
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the Rutgeerts endoscopic score relied on local endoscopic reports.
Finally, the time point for endoscopic assessment was not pre-
established and the response to treatment was not homogenously
assessed in all patients. Despite this, there were no differences be-
tween the 2 treatment groups regarding the time to therapeutic
endoscopic assessment.
In summary, anti-TNF therapy for endoscopic POR resulted in
a complete reversal of mucosal lesions in half of the patients and
clinical improvement in more than half of the symptomatic pa-
tients. We also found that the combination therapy of infliximab
and thiopurines resulted in a higher rate of mucosal improvement.
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Barrio, Hospital Universitario Rı́o Hortega (Valladolid, Spain); Olga
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11. López-SanrománA, Vera-Mendoza I, Domènech E, et al. Adalimumab vs
azathioprine in the prevention of postoperative Crohn’s disease
recurrence. A GETECCU randomised trial. J Crohns Colitis 2017;11:
1293–301.
12. Cañete F, Mañosa M, Casanova MJ, et al. Adalimumab or infliximab for
the prevention of early postoperative recurrence of Crohn disease: Results
from the ENEIDA registry. Inflamm Bowel Dis 2019;25:1862–70.
13. De Cruz P, KammMA, Hamilton AL, et al. Crohn’s disease management
after intestinal resection: A randomised trial. Lancet 2015;385:1406–17.
14. ReinischW, Angelberger S, PetritschW, et al. Azathioprine versus mesalazine
for prevention of postoperative clinical recurrence in patients with Crohn’s
diseasewith endoscopic recurrence:Efficacy and safety results of a randomised,
double-blind, double-dummy, multicentre trial. Gut 2010;59:752–9.
15. Sorrentino D, Terrosu G, Paviotti A, et al. Early diagnosis and treatment
of postoperative endoscopic recurrence of Crohn’s disease: Partial benefit
by infliximab-a pilot study. Dig Dis Sci 2012;57:1341–8.
16. Yamamoto T, Umegae S, Matsumoto K. Impact of infliximab therapy
after early endoscopic recurrence following ileocolonic resection of
Crohn’s disease: A prospective pilot study. Inflamm Bowel Dis 2009;
15(10):1460–6.
17. Assa A, Bronsky J, Kolho KL, et al. Anti-tnfa treatment after surgical
resection for Crohn’s disease is effective despite previous
pharmacodynamic failure. Inflamm Bowel Dis 2017;23:791–7.
18. Maaser C, Sturm A, Vavricka SR, et al. ECCO-ESGAR guideline for
diagnostic assessment in IBD part 1: Initial diagnosis, monitoring of
known IBD, detection of complications. J Crohns Colitis 2019;13:144–64.
19. Harris PA, Taylor R, Thielke R, et al. Research electronic data capture
(REDCap)—A metadata-driven methodology and workflow process for
providing translational research informatics support. J Biomed Inform
2009;42:377–81.
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3 Seventy percent of patients with CD develop POR within the
first year if no therapy is prescribed early after surgery.
3 Thiopurines and anti-TNF agents have proven to be efficient
in preventing endoscopic and clinical POR.
3 Whether universal prevention or endoscopy-driven therapy is
the best strategy is still under debate.
3 No data are available on the efficacy of anti-TNF agents in the
setting of asymptomatic patients with endoscopic POR.
WHAT IS NEW HERE
3 Anti-TNF therapy for endoscopic POR achieves a complete
reversal of mucosal lesions in almost half of the patients.
3 Combination therapy with thiopurines increases the likeliness
of improving mucosal lesions.
3 In the postoperative setting, infliximab seems to be superior to
adalimumab for improving recurrent lesions. However, face-
to-face prospective studies are needed in this setting.
TRANSLATIONAL IMPACT
3 Since this article is not a pre-clinical studywehave notmade a
translational impact.
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